

पेटेंट कार्यालय
शासकीय जर्नल

**OFFICIAL JOURNAL
OF
THE PATENT OFFICE**

निर्गमन सं. 26/2021
ISSUE NO. 26/2021

शुक्रवार
FRIDAY

दिनांक: 25/06/2021
DATE: 25/06/2021

पेटेंट कार्यालय का एक प्रकाशन
PUBLICATION OF THE PATENT OFFICE

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202121023370 A

(19) INDIA

(22) Date of filing of Application :25/05/2021

(43) Publication Date : 25/06/2021

(54) Title of the invention : A PROTEIN CONJUGATED (2-HYDROXYPROPYL)--CYCLODEXTRIN)-METHOTREXATE COMPLEX BEARING PLGA NANOPARTICLES

(51) International classification	:A61K0031519000, B82Y0005000000, A61K0047690000, A61K0009510000, A61K0049000000	(71) Name of Applicant : 1)Tanweer Haider Address of Applicant :Department of Pharmaceutical Sciences, Doctor Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India-470003 Madhya Pradesh India 2)Sanjay K. Jain 3)Vandana Soni
(31) Priority Document No	:NA	(72) Name of Inventor :
(32) Priority Date	:NA	1)Tanweer Haider
(33) Name of priority country	:NA	2)Sanjay K. Jain
(86) International Application No	:NA	3)Vandana Soni
Filing Date	:NA	
(87) International Publication No	: NA	
(61) Patent of Addition to Application Number	:NA	
Filing Date	:NA	
(62) Divisional to Application Number	:NA	
Filing Date	:NA	

(57) Abstract :

The present invention provides annexin-V (ANX) coupled nanoparticles loaded with the antitumor agents for evaluating and treating tumors. The present invention provides a pharmaceutical composition for treating tumors comprising a nanoparticle encapsulated inclusion complex of an antitumor agent coupled with annexin-V (ANX) for specifically targeting cancer cells, wherein the inclusion complex comprises a cyclic-oligosaccharide and methotrexate (MTX). Further, the present invention provides a method of preparation of the said nanoparticle encapsulated inclusion complex coupled with annexin-V (ANX). The present invention thus provides a drug delivery system for treatment of tumors, especially cancers based on discriminate distribution of the drug to cancer cells specifically and not to the normal cells thereby reducing any side effect.

No. of Pages : 28 No. of Claims : 10